Silencing RPL29 dramatically induced apoptosis in CML CD34+CD38− cells (Figure 5B), without an additive or synergistic effect when co‐treated with imatinib. Here, RPL29 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.